COVID-19: molecular targets, drug repurposing and new avenues for drug discovery.

Mem Inst Oswaldo Cruz

Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Bioquímica Experimental e Computacional de Fármacos, Rio de Janeiro, RJ, Brasil.

Published: October 2020

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infection that may break the healthcare system of several countries. Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as well as discussing opportunities for development of new treatments based on current knowledge of the mechanism of infection and potential targets within. Finally, we also discuss patent protection issues, cost effectiveness and scalability of synthetic routes for some of the most studied repurposing candidates since these are key aspects to meet global demand for COVID-19 treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534958PMC
http://dx.doi.org/10.1590/0074-02760200254DOI Listing

Publication Analysis

Top Keywords

drug repurposing
8
covid-19
4
covid-19 molecular
4
molecular targets
4
targets drug
4
repurposing avenues
4
avenues drug
4
drug discovery
4
discovery coronavirus
4
coronavirus disease
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!